#ASCO19 roundup: AstraZeneca, Merck score another Lynparza hit
CHICAGO — Lynparza continues to be the big cancer drug success story that AstraZeneca CEO Pascal Soriot so badly needs.
On Sunday, the pharma giant — along with their partners at Merck — released new data demonstrating that their leading PARP inhibitor spurred a significant increase in progression-free survival among BRCA-mutated pancreatic cancer patients when used as a frontline maintenance therapy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,200+ biopharma pros reading Endpoints daily — and it's free.